Replimune Group (NASDAQ:REPL) Shares Down 7.1% - What's Next?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) traded down 7.1% during mid-day trading on Wednesday . The company traded as low as $6.68 and last traded at $6.63. 129,158 shares changed hands during trading, a decline of 85% from the average session volume of 862,020 shares. The stock had previously closed at $7.14.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on REPL shares. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. BMO Capital Markets increased their price target on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright raised their price objective on Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $19.43.

Replimune Group Trading Up 2.2 %

The company has a fifty day moving average of $11.34 and a 200-day moving average of $11.89. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $578.38 million, a price-to-earnings ratio of -2.45 and a beta of 1.26.

Remove Ads

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, equities research analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Replimune Group

Several hedge funds have recently modified their holdings of the stock. Boxer Capital Management LLC purchased a new stake in Replimune Group during the 4th quarter worth $21,754,000. Tang Capital Management LLC grew its stake in shares of Replimune Group by 125.0% during the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock valued at $32,697,000 after acquiring an additional 1,500,000 shares in the last quarter. State Street Corp grew its stake in shares of Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock valued at $25,647,000 after acquiring an additional 1,182,181 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Replimune Group by 11.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock worth $132,761,000 after acquiring an additional 1,083,633 shares during the last quarter. Finally, MPM Bioimpact LLC acquired a new position in shares of Replimune Group in the fourth quarter worth about $11,504,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.